Loading…
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $4.0B | $1.2B | $869M | $849M | -3677.4% | 4.0% | 0.7% |
| 2024 | $3.9B | $1.2B | $863M | $864M | -680.2% | 2.2% | 9.4% |
| 2023 | $3.8B | $1.2B | $789M | $861M | -526.1% | -3.4% | -9.6% |
| 2022 | $3.9B | $1.2B | $873M | $738M | 3519.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,919.71 | 3,788.31 | 3,872.36 | 4,026.40 |
| Operating Revenue | - | 3,919.71 | 3,788.31 | 3,872.36 | 4,026.40 |
| Cost Of Revenue | - | 1,611.67 | 1,547.02 | 1,546.78 | 1,635.75 |
| Gross Profit | - | 2,308.04 | 2,241.29 | 2,325.58 | 2,390.65 |
| Operating Expense | - | 1,181.82 | 1,161.60 | 1,198.53 | 1,272.16 |
| Research And Development | - | 177.12 | 185.28 | 189.36 | 199.37 |
| Selling General And Administration | - | 938.46 | 904.11 | 936.30 | 998.31 |
| Total Expenses | - | 2,793.49 | 2,708.63 | 2,745.31 | 2,907.91 |
| Operating Income | - | 1,126.22 | 1,079.68 | 1,127.05 | 1,118.49 |
| EBITDA | - | 1,239.01 | 1,172.26 | 1,235.08 | 1,243.03 |
| Normalized EBITDA | - | 1,248.56 | 1,204.99 | 1,254.85 | 1,260.90 |
| EBIT | - | 1,125.98 | 1,051.09 | 1,111.85 | 1,117.42 |
| Interest Expense | - | 55.39 | 77.37 | 74.63 | 68.52 |
| Net Interest Income | - | -55.39 | -77.37 | -74.63 | -68.52 |
| Other Non Operating Income Expenses | - | 9.32 | 4.15 | 4.57 | 16.80 |
| Other Income Expense | - | -0.24 | -28.59 | -15.20 | -1.07 |
| Interest Expense Non Operating | - | 55.39 | 77.37 | 74.63 | 68.52 |
| Net Non Operating Interest Income Expense | - | -55.39 | -77.37 | -74.63 | -68.52 |
| Pretax Income | - | 1,070.59 | 973.73 | 1,037.22 | 1,048.91 |
| Tax Provision | - | 198.09 | 184.95 | 174.08 | 179.72 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -1.77 | -6.22 | -3.36 | -3.06 |
| Net Income Continuous Operations | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Net Income From Continuing And Discontinued Operation | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Net Income From Continuing Operation Net Minority Interest | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Net Income | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Net Income Common Stockholders | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Net Income Including Noncontrolling Interests | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Normalized Income | - | 880.29 | 815.29 | 879.55 | 884.01 |
| Diluted NI Availto Com Stockholders | - | 872.50 | 788.78 | 863.14 | 869.19 |
| Basic Average Shares | - | 22.49 | 21.85 | 21.22 | 20.61 |
| Diluted Average Shares | - | 22.72 | 21.97 | 21.32 | 20.67 |
| Reconciled Depreciation | - | 113.02 | 121.16 | 123.22 | 125.61 |
| Reconciled Cost Of Revenue | - | 1,564.88 | 1,498.07 | 1,496.43 | 1,584.61 |
| Total Unusual Items | - | -9.56 | -32.74 | -19.77 | -17.87 |
| Total Unusual Items Excluding Goodwill | - | -9.56 | -32.74 | -19.77 | -17.87 |
| Special Income Charges | - | -9.56 | -32.74 | -19.77 | -17.87 |
| Restructuring And Mergern Acquisition | - | 9.56 | 32.74 | 19.77 | 17.87 |
| Depreciation Amortization Depletion Income Statement | - | 66.24 | 72.21 | 72.87 | 74.47 |
| Depreciation And Amortization In Income Statement | - | 66.24 | 72.21 | 72.87 | 74.47 |
| Amortization | - | 66.24 | 72.21 | 72.87 | 74.47 |
| Amortization Of Intangibles Income Statement | - | 66.24 | 72.21 | 72.87 | 74.47 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Mettler-Toledo International Inc.this co. | MTD | $23.9B | 27.44↑ premium | - | -3676.8% | 20.87 |
| DexCom, Inc. | DXCM | $28.0B | 33.49 | 10.20 | 30.5% | 20.97 |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| West Pharmaceutical Services, Inc. | WST | $22.4B | 45.41 | 7.06 | 15.5% | 28.40 |
| Quest Diagnostics Incorporated | DGX |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $21.7B |
| 21.88 |
| 3.03 |
| 13.8% |
| 12.88 |
| Labcorp Holdings Inc. | LH | $21.4B | 24.41 | 2.48 | 10.2% | 13.61 |
| STERIS plc | STE | $20.7B | 26.48 | 2.88 | 10.9% | 14.02 |
| Moderna, Inc. | MRNA | $20.5B | -7.25 | 2.37 | -32.6% | -7.54 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Peer Median | - | 23.15 | 3.47 | 12.4% | 13.61 | |